Kimia Bagheri

Dr. Kimia Bagheri

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2024 in Journal of Infection and Public Health
Verified
Journal Article
Open access
HBHamed Behniafar
Hamed Behniafar
MSMahdi Sepidarkish
Mahdi Sepidarkish
MTMehrdad Jafari Tadi
Mehrdad Jafari Tadi
SVSoghra Valizadeh
Soghra Valizadeh
MGMostafa Gholamrezaei
Mostafa Gholamrezaei
ARAli Rostami
Ali Rostami
This systematic review and meta-analysis study aimed to evaluate global Trichuris infection prevalence, assessing progress towards the WHO's 2030 target. We searched international databases from 2010-2023, categorizing data by regions and socio-economic variables using a random-effects model. Analyzing 757 articles covering 7154,842 individuals from 78 countries, the study found a pooled global prevalence of (6.64-7.57%), with the highest rates in the Caribbean (21.72%; 8.90-38.18%) and South-East Asia (20.95; 15.71-26.71%) regions. Southern Africa (9.58; 2.11-21.46%), Latin America (9.58; 2.11-21.46%), and Middle Africa Middle Africa (8.94; 6.31-11.98%) also exhibited high prevalence. Eastern Europe had the lowest prevalence at 0.16% (0.09-0.24). Approximately 513 (480-547) million people worldwide were estimated to harbor Trichuris. Moreover ∼1.5% of people tested worldwide (2010-2023) had a moderate to heavy intensity of infection. The study emphasizes the persistent global health threat of Trichuris infection, urging tailored strategies for effective control and prevention on a global scale.

22 July 2023 in Cancers
Verified
Journal Article
Open access
PDF file
SKSaeed Khalili
Saeed Khalili
FZFatemeh Zeinali
Fatemeh Zeinali
AFAtousa Moghadam Fard
Atousa Moghadam Fard
STSeyed Reza Taha
Seyed Reza Taha
ANAndarz Fazlollahpour Naghibi
Andarz Fazlollahpour Naghibi
ZPZahra Payandeh
Zahra Payandeh
Macrophages are types of immune cells, with ambivalent functions in tumor growth, which depend on the specific environment in which they reside. Tumor-associated macrophages (TAMs) are a diverse population of immunosuppressive myeloid cells that play significant roles in several malignancies. TAM infiltration in malignancies has been linked to a poor prognosis and limited response to treatments, including those using checkpoint inhibitors. Understanding the precise mechanisms through which macrophages contribute to tumor growth is an active area of research as targeting these cells may offer potential therapeutic approaches for cancer treatment. Numerous investigations have focused on anti-TAM-based methods that try to eliminate, rewire, or target the functional mediators released by these cells. Considering the importance of these strategies in the reversion of tumor resistance to conventional therapies and immune modulatory vaccination could be an appealing approach for the immunosuppressive targeting of myeloid cells in the tumor microenvironment (TME). The combination of reprogramming and TAM depletion is a special feature of this approach compared to other clinical strategies. Thus, the present review aims to comprehensively overview the pleiotropic activities of TAMs and their involvement in various stages of cancer development as a potent drug target, with a focus on hematologic tumors.

1 May 2025 in Current Pharmaceutical Biotechnology
Verified
Journal Article
Closed access
PDF file
STSeyed Reza Taha
Seyed Reza Taha
ANAndarz Fazlollahpour Naghibi
Andarz Fazlollahpour Naghibi
MZMahdieh Shariat Zadeh
Mahdieh Shariat Zadeh
KBKimia Bagheri
Kimia Bagheri
HYHamed Rahmani Youshanlouei
Hamed Rahmani Youshanlouei
SMSaba Mehrtabar
Saba Mehrtabar
Treatment of hepatic diseases presents a significant challenge due to their diverse nature. Ginsenosides, bioactive compounds derived from the root of Panax ginseng and widely used in traditional Chinese medicine, offer multifaceted protection to various organs in the body. Their versatile effects, including antioxidant, anti-inflammatory, anti-apoptotic and more, make them a promising approach for addressing hepatic disorders. This review explores the intricate molecular mechanisms and properties of ginsenosides in the prevention and treatment of liver ailments, from mild conditions to severe damage and liver fibrosis. Given the increasing prevalence of hepatic disorders, this article sheds light on the significant pharmaceutical potential of ginsenosides in the realm of hepatic disease management.

26 February 2026 in Toxins
Verified
Journal Article
Open access
PDF file
RHReza Mosaddeghi Heris
Reza Mosaddeghi Heris
MPMojtaba Pandeh
Mojtaba Pandeh
LGLeila Ghorbi
Leila Ghorbi
NTNiloofar Taheri
Niloofar Taheri
MZMaedeh Shariat Zadeh
Maedeh Shariat Zadeh
PMPaolo Martelletti
Paolo Martelletti
Peptides from scorpion venom, mainly in species such as Olivierus martensii (formerly Olivierus martensii Karsch, often designated BMK) (BmK) and Tityus serrulatus from the Buthidae family, show real promise as painkillers that skip opioids altogether. They work by hitting specific ion channels and dialing down inflammation. This review gathers information on their molecular setups: disulfide-bridged types and those without, weighing in at 3 to 10 kilodaltons (kDa). Structural features include motifs stabilized by cysteines. In pain signaling, they block voltage-gated sodium channels (NaV) such as NaV1.7 and NaV1.8; take the BmK analgesic–antitumor peptide (BmK-AGAP) for example. Additionally, scorpion venom heat-resistant peptide (SVHRP) reduces microglia activity. Tests on rodents using formalin injections, acetic acid writhing, and chronic constriction injury (CCI) setups reveal pain relief that depends on dose and stacks up to morphine. Pairings like AGAP with lidocaine decrease the effective dose by half. In terms of safety, therapeutic levels have low-toxicity with a median lethal dose (LD50) over 20 mg/kg. Issues crop up with immune responses, unintended targets, and differences in venom batches. Clinical information remains thin, so gaps persist. Engineered versions could change the game for neuropathic pain, inflammatory conditions, and cancer-related discomfort. Standardization plus Phase I studies would help move this forward.

21 September 2026 in Neuroradiology
Verified
Journal Article
Closed access
PDF file
RHReza Mosaddeghi Heris
Reza Mosaddeghi Heris
KBKimia Bagheri
Kimia Bagheri
AAAli Adib
Ali Adib
ATAmir Tahavvori
Amir Tahavvori
HSHadi Sahrai
Hadi Sahrai
HSHouman Sotoudeh
Houman Sotoudeh

Verified
Journal Article
Open access
PDF file
HSHadi Sahrai
Hadi Sahrai
RHReza Mosaddeghi Heris
Reza Mosaddeghi Heris
NFNasrin . Forghani
Nasrin . Forghani
ANAli Norouzi
Ali Norouzi
SZSahand Zare
Sahand Zare
MFmaryam farzaneh
maryam farzaneh
Malignant gliomas are highly aggressive primary brain tumors for which the therapeutic efficacy of cisplatin is frequently limited by intrinsic or acquired drug resistance. Despite advances in adjuvant therapies, overcoming chemoresistance remains a major challenge in the treatment of these malignancies. Emerging evidence indicates that long non-coding RNAs (lncRNAs), a class of non-protein-coding transcripts involved in gene regulation, play important roles in modulating treatment responses. Several lncRNAs, including differentiation antagonizing non-protein-coding RNA (DANCR), HOXD antisense growth-associated long non-coding RNA (HOXD-AS1), MEG3, MALAT1, and HOTAIR, have been implicated in pathways associated with glioma progression and therapeutic resistance. In particular, DANCR has been reported to promote cisplatin resistance in glioma cells through suppression of apoptosis and activation of pro-survival signaling pathways. This review summarizes current evidence regarding the roles of lncRNAs in cisplatin resistance, highlighting mechanisms such as regulation of drug transport, DNA damage repair, apoptosis, cancer stem-cell maintenance, and signaling pathways associated with treatment adaptation. We also discuss current limitations, challenges for clinical translation, and gaps in the existing evidence. A better understanding of lncRNA-mediated resistance mechanisms may facilitate the identification of novel therapeutic targets and inform future studies aimed at overcoming cisplatin resistance in malignant gliomas.